【药物名称】Ipidacrine hydrochloride hydrate, Amiridine, NIK-247, Senita
化学结构式(Chemical Structure):
参考文献No.3117
标题:9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrate hydrochloride as stimulant of neuro-muscular transmission of smooth muscles
作者:(Nauchno-Issledovatelsky Institut)
来源:US 4550113
合成路线图解说明:

By reaction of 2-aminocyclopent-1-ene-1-carbonitrile (I) with cyclohexanone (II) in presence of polyphosphoric acid in benzene followed by treatment with hydrochloric acid in ethanol.

参考文献No.7748
标题:Pharmaceutical preparation for learning stimulation and memory improvement
作者:Lavretskaya, E.F.; Upadysheva, A.V.; Znamenskaya, A.P.; Sukhanova, S.A.; Grigorieva, N.D.; Penke, I.K.; Timofeeva, A.K. (Nauchno-Issledovatelsky Institut)
来源:GB 2192129; US 4735953
合成路线图解说明:

By reaction of 2-aminocyclopent-1-ene-1-carbonitrile (I) with cyclohexanone (II) in presence of polyphosphoric acid in benzene followed by treatment with hydrochloric acid in ethanol.

参考文献No.243654
标题:NIK-247
作者:Graul, A.; Casta馿r, J.; Prous, J.
来源:Drugs Fut 1994,19(4),343
合成路线图解说明:

By reaction of 2-aminocyclopent-1-ene-1-carbonitrile (I) with cyclohexanone (II) in presence of polyphosphoric acid in benzene followed by treatment with hydrochloric acid in ethanol.

参考文献No.346256
标题:Synthesis of estimated metabolites of 9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinoline monohydrochloride monohydrate (NIK-247). I.Synthesis of mono-hydroxylated metabolites
作者:Komatsu, T.; Yano, M.; Inada, H.; Iwamoto, M.; Okada, K.; Suzuki, K.
来源:Yakugaku Zasshi 1995,115(12),1016
合成路线图解说明:

The monohydroxylated metabolite of NIK-247, (+)-9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-8-ol (VI) has been synthesized as follows: The condensation of cyclohexane-1,3-dione (I) with 2-amino-1-cyclopentene-1-carbonitrile (II) by means of PPE gives 2-(3-oxo-1-cyclohexen-1-yl)-1-cyclopentene-1-carbonitrile (III), which is cyclized by means of BF3.Et2O to yield 9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-8-one (IV). The reduction of (IV) with NaBH4 affords the corresponding racemic alcohol (V), which is submitted to optical resolution with (+)-di-p-toluyltartaric acid to give the desired compound (VI).

合成路线图解说明:

The monohydroxylated metabolite of NIK-247, (+)-9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-1-ol (XII) has been synthesized as follows: The condensation of cyclopentane-1,3-dione (VIII) with 2-amino-1-cyclohexene-1-carbonitrile (VII) by means of PPE gives 2-(3-oxo-1-cyclopenten-1-yl)-1-cyclohexene-1-carbonitrile (IX), which is cyclized by means of BF3.Et2O to yield 9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-1-one (X). The reduction of (X) with NaBH4 affords the corresponding racemic alcohol (XI), which is submitted to optical resolution with (+)-di-p-toluyltartaric acid to give the desired compound (XII).

参考文献No.346260
标题:Synthesis of estimated metabolites of 9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinoline monohydrochloride monohydrate (NIK-247). II. Synthesis of dihydroxylated metabolites
作者:Komatsu, T.; Yano, M.; Iwamoto, M.; Kobayashi, M.; Suzuki, K.
来源:Yakugaku Zasshi 1995,115(12),1022
合成路线图解说明:

The synthesis of two dihydroxylated metabolites of NIK-247 has been reported: Two diastereomeric isomers 9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinoline-1,8-diol (VI) and (VII) have been synthesized as follows. The oxidation of 2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-amine (I) with CrO3.H2SO4 gives 9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinoline-1,8-dione (II), which is selectively reduced with 1 equivalent of NaBH4 yielding a mixture of the two hydroxyketones (III) and (IV), separated by crystallization. The optical resolution of (III) with (-)-di-p-toluyltartaric acid affords the pre (+)-isomer (V), which is further reduced with NaBH4 to afford a diastereomeric mixture of the 1,8-diols (VI) and (VII), which is separated by HPLC over Chiracel OG in n-hexane ethanol (9:1).

Drug Information Express,Drug R&D,Chemical Database,Patent Search.
Copyright © 2006-2024 Drug Future. All rights reserved.Contact Us